Publications by authors named "Melanie Ayala Ceja"
Article Synopsis
- Cytokine release syndrome (CRS) is a common side effect of CAR-T cell therapy, but researchers have developed self-regulating T cells that help reduce its severity by secreting cytokine inhibitors.
- In preclinical studies using a humanized mouse model, T cells that secrete a modified version of tocilizumab (Toci) showed less CRS-related toxicity and improved safety compared to traditional tocilizumab treatment.
- Additionally, these Toci-secreting CAR-T cells demonstrated better antitumor effects and enhanced the presence of beneficial T-cell types in the tumor microenvironment, indicating a promising strategy for making CAR-T therapy safer and more effective.
Chimeric antigen receptor (CAR)-T cell therapies have demonstrated strong curative potential and become a critical component in the array of B-cell malignancy treatments. Successful deployment of CAR-T cell therapies to treat hematologic and solid cancers, as well as other indications such as autoimmune diseases, is dependent on effective CAR-T cell manufacturing that impacts not only product safety and efficacy but also overall accessibility to patients in need. In this review, we discuss the major process parameters of autologous CAR-T cell manufacturing, as well as regulatory considerations and ongoing developments that will enable the next generation of CAR-T cell therapies.
View Article and Find Full Text PDFUnlabelled: To address antigen escape and loss of T-cell functionality, we report a phase I clinical trial (NCT04007029) evaluating autologous naive and memory T (TN/MEM) cells engineered to express a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR; CART19/20) for patients with relapsed/refractory non-Hodgkin lymphoma (NHL), with safety as the primary endpoint. Ten patients were treated with 36 × 106 to 165 × 106 CART19/20 cells. No patient experienced neurotoxicity of any grade or over grade 1 cytokine release syndrome.
View Article and Find Full Text PDF